1. Pink Sheet
  2. >>Product Reviews
  3. >>Approvals

Kuwait’s New Fast-Track Approval System Follows Regional Trend

 
• By Francesca Bruce

Kuwait is the latest market in the Middle East to introduce a new regulatory procedure for speeding up market entry of innovative new drugs. However, industry experts would like to see it go further.

Kuwait flag
Kuwait has introduced a new fast track approval procedure

In line with other markets in the Middle East, Kuwait has introduced a new fast-track approval system that will speed up market entry for certain innovative new medicines. Industry experts have welcomed the move but would like the Kuwaiti system to go further and include a wider range of products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews

PharmaMar Seeks EU Fast-Track Status For ‘Practice-Changing’ ES-SCLC Therapy

 
• By Neena Brizmohun

PharmaMar, which wants to use the Jazz Pharmaceuticals-partnered drug, lurbinectedin, in combination with Roche’s Tecentriq for treating extensive-stage small cell lung cancer, is one of two companies that this month sought an accelerated assessment of their planned EU marketing applications.

US FDA Miss On Stealth’s Elamipretide Boosts Signal Of Broader Delays Due To Staff Cuts

 
• By Sue Sutter

Failing to meet the 29 April user fee date for the Barth syndrome treatment, and CDER’s request for a delay in responding to Vanda’s appeal of a tradipitant complete response letter, suggest a slowdown in review work due to layoffs and other recent changes.

Potency Assay Issues Delayed US FDA Approval Of Mesoblast’s Ryoncil For Years

 
• By Sue Sutter

The company’s failure to show its potency assays measured attributes directly related to the mesenchymal stromal cell product’s therapeutic effect highlights the importance of a robust CMC program for complex cell therapies.